Monopar Therapeutics Inc./$MNPR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Ticker
$MNPR
Sector
Primary listing
Employees
22
Headquarters
Website
MNPR Metrics
BasicAdvanced
$349m
-
-$1.85
1.65
-
Price and volume
Market cap
$349m
Beta
1.65
52-week high
$105.00
52-week low
$28.40
Average daily volume
172k
Financial strength
Current ratio
51.353
Quick ratio
51.33
Long term debt to equity
0.112
Total debt to equity
0.178
Profitability
Management effectiveness
Return on assets (TTM)
-10.39%
Return on equity (TTM)
-14.22%
Valuation
Price to book
2.53
Price to tangible book (TTM)
2.53
Price to free cash flow (TTM)
-31.676
Free cash flow yield (TTM)
-3.16%
Free cash flow per share (TTM)
-1.646
Growth
Earnings per share change (TTM)
-54.99%
3-year earnings per share growth (CAGR)
-23.50%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Monopar Therapeutics Inc. stock?
Monopar Therapeutics Inc. (MNPR) has a market cap of $349M as of May 02, 2026.
What is the P/E ratio for Monopar Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Monopar Therapeutics Inc. (MNPR) stock is 0 as of May 02, 2026.
Does Monopar Therapeutics Inc. stock pay dividends?
No, Monopar Therapeutics Inc. (MNPR) stock does not pay dividends to its shareholders as of May 02, 2026.
When is the next Monopar Therapeutics Inc. dividend payment date?
Monopar Therapeutics Inc. (MNPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Monopar Therapeutics Inc.?
Monopar Therapeutics Inc. (MNPR) has a beta rating of 1.65. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.